Which is right for me?
Find the treatment that fits your life.
Answer two questions for a steer, compare the options side by side, then let a UK prescriber make the call.
Two questions
Answer both questions and a suggestion appears here, with the reason. Your prescriber makes the final decision from your assessment.
Eligibility
Who prescription treatment is for.
For adults whose weight is affecting their health, when diet and activity alone have not been enough. These are the licensed criteria; the prescriber confirms suitability from your full assessment.
01
BMI 30 or above
Or 27 and above with a weight-related condition such as high blood pressure, prediabetes or sleep apnoea.
02
Aged 18 to 74
Lower BMI thresholds apply for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds.
03
Not pregnant or breastfeeding
And not planning a pregnancy during treatment. Contraception is discussed in the assessment.
04
No history of certain conditions
Medullary thyroid cancer, MEN2 or pancreatitis rule treatment out. Your prescriber asks about other conditions and medicines.
Meeting the criteria does not guarantee treatment. Height, weight and identity are checked before anything is prescribed.
Side by side
A weekly pen or a daily tablet?
Both routes are reviewed by the same prescribing team. The pens lead on results; the tablets lead on routine.
| Feature |  Weekly injection |  Daily tablet |
|---|---|---|
| How often | Once a week | Once a day |
| Needles | One small pen injection, under the skin | None |
| Food and timing rules | None | Wegovy tablets: empty stomach, first thing. Foundayo: none |
| Average loss in the trials | Up to 22.5% of body weight | Up to 16.6% of body weight |
| Heart-health evidence | Wegovy: 20% fewer major heart events (SELECT) | Not yet shown for the tablets |
| Storage | In the fridge, then up to a month at room temperature | Room temperature |
| Price at Cuva | From £89.99 per pen | From £94.99 per pack |
| Best when | You want the strongest results and one thing to remember a week | You would rather not inject, or travel without a fridge |
Trial averages at 64 to 72 weeks alongside diet and activity advice, at the highest dose. Results vary from person to person.
The four treatments
Every option, on one page.
One injection a week
Mounjaro.
Tirzepatide
Learn moreNew patient offer
- Use code FIRSTWL10for £10 off
- Use code FIRSTWL25for £25 off 7.5mg to 15mg
22.5%average loss, 72 weeks
One injection a week
Wegovy.
Semaglutide
Learn moreNew patient offer
- Use code FIRSTWL10for £10 off
20.7%average loss, 68 weeks
One tablet each morning
Wegovy tablets.
Semaglutide
Learn moreNew patient offer
- Use code FIRSTWL10for £10 off
16.6%average loss, 64 weeks
One tablet a day, any time
Foundayo.
Orforglipron
Learn moreNew patient offer
- Use code FIRSTWL10for £10 off
12.4%average loss, 72 weeks
Your history
Conditions, other medicines, past reactions and anything that rules a treatment out.
What you have taken before
A previous pen or tablet, the dose you reached and how you got on with it.
Your routine
Travel, fridge access, mornings, needles, and how many things you want to remember.
Not the price
The prescriber never sees a reason to steer you to a dearer option.
Still not sure?
You do not have to decide alone.
Leave the treatment open in the assessment and the prescriber recommends one from your answers. This is what they weigh up.
Choosing? The questions we hear most.
Straight answers from the clinical team on picking between the pens and the tablets.
Or email support@cuvahealth.co.uk
Frequently asked
Which weight loss treatment gives the best results?
In the pivotal trials, Mounjaro (tirzepatide) produced the largest average loss at 22.5% of body weight over 72 weeks, followed by Wegovy (semaglutide) at 20.7% over 68 weeks. Of the tablets, Wegovy tablets averaged 16.6% over 64 weeks and Foundayo 12.4% over 72 weeks. Averages hide a wide range, and the treatment you stay on is the one that works.
Is a tablet as effective as an injection?
Not quite, on the trial averages. The tablets are a good fit if you would rather not inject, need to travel without a fridge, or want the simplest routine. Your prescriber can move you between routes later if the first choice is not working.
Do I choose the treatment or does the prescriber?
You can ask for a treatment in the assessment, and most people who are suitable get the one they ask for. The prescriber checks it against your history, other medicines and what you have taken before, and suggests an alternative where there is a clinical reason to.
Can I switch between treatments later?
Yes. Moving from a tablet to an injection, or between the two pens, is a new assessment with your prescriber. They pick a sensible starting dose so you do not have to begin again from the lowest strength where that is safe.
What if I am not eligible?
The free assessment tells you quickly. Cuva does not prescribe outside the licensed criteria, and there is nothing to pay if treatment is not suitable.
I am already on treatment elsewhere. Which do I choose?
Choose the treatment you are on now and tell Cuva your current dose in the assessment, with a photo of your prescription or packaging. Where it is safe, your prescriber continues you at the same step. The switching page explains what is needed.
Ready when you are.
Start with a short, free online assessment. A UK prescriber takes it from there.
Not for emergencies. Call 999, or NHS 111 for urgent advice.